Reply

Affiliations

¹ Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
² Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, China.
³ Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout Affiliated Hospital of Qingdao University, Institute of Metabolic Diseases, Qingdao University and Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China.

Comment

Xiaomei Xue et al. Arthritis Rheumatol. 2023 Sep.

. 2023 Sep;75(9):1681-1683.

doi: 10.1002/art.42494. Epub 2023 Jun 14.

¹ Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China.
² Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout, the Affiliated Hospital of Qingdao University, Qingdao, China.
³ Department of Endocrinology and Metabolism, Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout Affiliated Hospital of Qingdao University, Institute of Metabolic Diseases, Qingdao University and Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Qingdao, China.

No abstract available

Comment on

Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Kawada T. Kawada T. Arthritis Rheumatol. 2023 Sep;75(9):1680-1681. doi: 10.1002/art.42499. Epub 2023 Jun 14. Arthritis Rheumatol. 2023. PMID: 36908047 No abstract available.

1. Yan F, Xue X, Lu J, et al. Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion. Arthritis Rheumatol 2022;74:2015-23.
1. Liang N, Sun M, Sun R, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther 2019;21:200.
1. Bohm M, Vuppalanchi R, Chalasani N, et al. Febuxostat-induced acute liver injury. Hepatology 2016;63:1047-9.
1. Nishino M, Egami Y, Nakamura H, et al. Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study. Health Sci Rep 2022;5:e563.
1. Xue X, Yuan X, Han L, et al. Effect of clinical typing on serum urate targets of benzbromarone in Chinese gout patients: a prospective cohort study. Front Med (Lausanne) 2021;8:806710.